Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 4Recruiting 3Active not recruiting 3Unknown 2Withdrawn 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma 2Burkitt Lymphoma 2Recurrence 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell 1Leukemia, Prolymphocytic 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Leukemia 1Hematologic Neoplasms 1

Interventions

Cytarabine 4fludarabine phosphate 3fludarabine 3Methotrexate 3merphos 2Pentetic Acid 2Methylprednisolone 2Hydrocortisone 2Cyclophosphamide 2Biopsy 2revumenib 1pegaspargase 1ixazomib 1hydrocortisone hemisuccinate 1ethanolamine oleate 1asparaginase erwinia chrysanthemi recombinant 1X-Rays 1Whole-Body Irradiation 1Vincristine 1Trimethoprim, Sulfamethoxazole Drug Combination 1Trimethoprim 1Sulfamethoxazole 1Stem Cell Transplantation 1Specimen Handling 1Sodium Chloride 1Sirolimus 1Saline Solution, Hypertonic 1Saline Solution 1Radiotherapy 1Psychiatric Rehabilitation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Leukemia, Biphenotypic, Acute × Asparaginase × Clear all
NCT02718755 2018-06-26

Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies

M.D. Anderson Cancer Center

Phase 2 Withdrawn
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Recurrence, Leukemia, Biphenotypic, Acute, Leukemia, Prolymphocytic, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡